While a diminished antibody response is anticipated after both CD19 and BCMA CAR-T due to on-target, off-tumor effects on B lymphocytes and plasma cells, the pathogen-specific antibody response is more significantly impaired after BCMA CAR-T compared to CD19 CAR-T, likely due to the impact of BCMA CAR-T on antibody-producing plasma cells [7]. The gene discussed is CD19; the disease is neoplasm.